These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19731330)

  • 1. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
    Thompson BW; Miller ST; Rogers ZR; Rees RC; Ware RE; Waclawiw MA; Iyer RV; Casella JF; Luchtman-Jones L; Rana S; Thornburg CD; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik S; Howard TH; Luck L; Wang WC
    Pediatr Blood Cancer; 2010 Feb; 54(2):250-5. PubMed ID: 19731330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
    McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
    Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hydroxyurea on clinical events in the BABY HUG trial.
    Thornburg CD; Files BA; Luo Z; Miller ST; Kalpatthi R; Iyer R; Seaman P; Lebensburger J; Alvarez O; Thompson B; Ware RE; Wang WC;
    Blood; 2012 Nov; 120(22):4304-10; quiz 4448. PubMed ID: 22915643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
    Miller ST; Rey K; He J; Flanagan J; Fish BJ; Rogers ZR; Wang WC; Ware RE;
    Pediatr Blood Cancer; 2012 Jul; 59(1):170-2. PubMed ID: 21744485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
    Lebensburger JD; Miller ST; Howard TH; Casella JF; Brown RC; Lu M; Iyer RV; Sarnaik S; Rogers ZR; Wang WC;
    Pediatr Blood Cancer; 2012 Oct; 59(4):675-8. PubMed ID: 22190441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
    Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
    Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.
    Alvarez O; Miller ST; Wang WC; Luo Z; McCarville MB; Schwartz GJ; Thompson B; Howard T; Iyer RV; Rana SR; Rogers ZR; Sarnaik SA; Thornburg CD; Ware RE;
    Pediatr Blood Cancer; 2012 Oct; 59(4):668-74. PubMed ID: 22294512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to study medication and visits: data from the BABY HUG trial.
    Thornburg CD; Rogers ZR; Jeng MR; Rana SR; Iyer RV; Faughnan L; Hassen L; Marshall J; McDonald RP; Wang WC; Huang X; Rees RC;
    Pediatr Blood Cancer; 2010 Feb; 54(2):260-4. PubMed ID: 19856395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
    Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
    Brandow AM; Panepinto JA
    Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term hydroxyurea treatment in young sickle cell patients.
    Maier-Redelsperger M; Labie D; Elion J
    Curr Opin Hematol; 1999 Mar; 6(2):115-20. PubMed ID: 10088642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.